68. CRISPR and molecular aging

<p>What do CRISPR and longevity have in common? Not much, except it's all molecular.</p> <p>We speak to two different CEOs focused on improving human health. We begin with Dr Benjamin Oakes, Co-Founder, President, and CEO of Scribe Therapeutics who takes us through the discovery, potential, and possible limitations of CRISPR.</p> <p>Then we are joined by fellow visionary, Kristen Fortney, the CEO and co-founder of BioAge, which is a clinical stage biotechnology company developing therapies that treat disease by targeting the biology of ageing.</p> <p>You cannot miss these fascinating conversations.</p> <p><strong>Keywords</strong>: ageing, crispr, molecules, age, technology, disease, muscle, engineering, treat, understand, genome editing, human, jennifer doudna.</p>